Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated thoracic radiotherapy plus adebrelimab and chemotherapy for extensive-stage small-cell lung cancer
ChiCTR2600118504Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600118504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118504.